人类免疫缺陷病毒阳性患者全髋关节置换术:10至14年简明随访
本研究对31例HIV阳性全髋关节置换术受者(41髋)进行扩展随访,新增2髋翻修(一例无菌性松动、一例假体周围骨折)和5例对侧全髋关节置换术,共5髋(13.8%)需翻修;Kaplan-Meier生存率2年93%、5年90%、10年和14年均为81%。作者认为HIV阳性患者术后感染发生率低,非血友病HIV阳性患者翻修率与既往报道的年龄相近HIV阴性患者相当。
要点
- 31例HIV阳性全髋关节置换术受者共41髋,随访至最近一次时5髋(13.8%)需翻修。
- 以任何原因翻修为终点的Kaplan-Meier生存率:2年93%、5年90%、10年和14年均为81%。
- 作者认为非血友病HIV阳性患者翻修率与既往报道的年龄相近HIV阴性患者相当。
核心结论
- 作者认为HIV阳性全髋关节置换术受者术后感染发生率可能较低。
- 作者认为非血友病HIV阳性患者翻修率与既往报道的年龄相近HIV阴性患者相当,凸显了高效抗逆转录病毒治疗的临床疗效。
研究设计与样本
- 本研究是对既往已发表研究的随访,原队列包含31例HIV阳性全髋关节置换术受者的41髋。
- 本次随访中,原队列有5例患者因对侧需行全髋关节置换术。
- 术后并发症记录至患者最近一次随访日期,采用Kaplan-Meier法以翻修全髋关节置换术为终点进行生存分析。
主要发现
- 自上次报告以来,新增2髋翻修(一例为无菌性松动,一例为假体周围骨折),另有5例患者行对侧全髋关节置换术。
- 最近一次随访时共有5髋(13.8%)需翻修全髋关节置换术。
- 原队列平均随访间隔为78.9±50.2个月,对侧5髋平均随访间隔为54.6±45.3个月。
- 以任何原因翻修为终点的Kaplan-Meier生存率分别为:初次全髋关节置换术后2年93%、5年90%、10年和14年均为81%。
关键数值与推荐
- 翻修全髋关节置换术共5髋,占13.8%。
- Kaplan-Meier生存率:2年93%、5年90%、10年和14年均为81%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advancements in the management of human immunodeficiency virus (HIV) now permit HIV-positive patients to have longer life spans, increasing their cumulative risk of developing an advanced degenerative joint disease, necessitating total hip arthroplasty (THA). The purpose of this study was to provide an extended follow-up on a previously published study on a cohort of HIV-positive THA recipients in an effort to confirm the safety and longevity of THA in this population. METHODS: This study is a follow-up on a previous study comprised of 41 hips in 31 HIV-positive THA recipients. At this follow-up, 5 patients from the original cohort required contralateral THA. Postoperative complications were recorded up to the patient's last follow-up date. A survivorship analysis was performed using the Kaplan-Meier method with revision THA as the end point. RESULTS: Since the last report, 2 additional hips were revised (one for aseptic loosening and one for a periprosthetic fracture), and 5 patients underwent contralateral THA. This resulted in a total of 5 (13.8%) hips requiring revision THA at the latest follow-up. The mean follow-up interval for the original cohort and for the contralateral 5 hips was 78.9 ± 50.2 months and 54.6 ± 45.3 months, respectively. Kaplan-Meier survivorship analysis with revision THA for any reason as the end point demonstrated survivorship of 93% (2 years), 90% (5 years), and 81% (10 and 14 years) after primary THA, respectively. CONCLUSION: Our study suggests that it is possible to achieve a low incidence of postoperative infection in HIV-positive THA recipients. In addition, our study demonstrates that non-hemophiliac HIV-positive patients have comparable revision rates to previously published reports on HIV-negative patients of similar age, underscoring the clinical efficacy of highly active antiretroviral therapy.
引用
- Novikov D, Anoushiravani AA, Chen KK, et al. Total Hip Arthroplasty in Human Immunodeficiency Virus-Positive Patients: A Concise Follow-Up at 10 to 14 Years. J Arthroplasty. 2018. PMID: 30503321. doi:10.1016/j.arth.2018.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。